Skip to main content Skip to footer
Dhenne Avocats
  • Dhenne Avocats
  • Firm
    • Our team
    • Join us
  • Expertise
    • Expertise
    • Patents
    • UPC
    • FRAND and SEPs
    • Pharma and SPCs
    • Trade secrets
    • Saisie-contrefaçon
    • Contracts
    • Patent valuation
    • Employee inventions
    • All fields of expertise
  • Services
    • Patent litigation
    • Bringing an infringement action
    • Infringement defence
    • Invalidity action
    • Provisional measures
    • Evidence before the UPC
    • The FRAND undertaking
    • Arbitration and mediation
    • Advice:
    • Second opinion
    • Litigation readiness
    • Saisie-contrefaçon preparedness
    • Trade secret audit
    • IP due diligence
    • Local counsel in France
    • Japan and Europe
    • Defensible portfolio
    • Litigation funding
    • All services
  • Technologies
    • Technical fields
    • Electronics
    • Telecoms and FRAND
    • Pharmaceuticals
    • Medical devices
    • Chemistry
    • Biotechnology
    • Mechanical engineering
  • Publications
    • Blog
    • Kluwer Patent Blog
    • Journals and books
    • Speaking engagements
    • Patent litigation news
    • Consultation responses
    • Glossary
    • All publications
  • Le Lab
    • UPC Litigation Watch
    • UPC decisions analysed
    • UPC statistics
    • FRAND Litigation Watch
    • FRAND decisions analysed
    • Pharma Litigation Watch
    • Pharma decisions analysed
    • Subscribe to the watch
  • Contact
    • fr
    • en
    • ja
Back to blog

Category : Patents

23 October 2026
Biogaran v. Lundbeck and the Challenger’s Burden in Second Medical Use Cases
23 October 2026
Biogaran v. Lundbeck and the Challenger’s Burden in Second Medical Use Cases
  • Patents
  • Litigation
  • UPC
  • Pharmaceuticals
  • Sufficiency of disclosure
12 October 2026
Publication of A Contractual Theory of FRAND (Wolters Kluwer, 2026)
  • Patents
  • FRAND
12 October 2026
Compulsory licence on a patent application: an idea making its way
  • Patents
  • Litigation
  • Contract
  • Pharmaceuticals
11 October 2026
An opt-out is not a register entry: ownership and procedural choice before the UPC
  • Patents
  • Litigation
  • UPC
  • Case law
10 October 2026
Pleading the long arm: what a UPC statement of claim must carry
  • Patents
  • Litigation
  • Forum shopping
  • UPC
9 October 2026
Entering the European market: the four questions that decide the timetable
  • Patents
  • Litigation
  • Forum shopping
  • UPC
8 October 2026
Munich’s FRAND guidelines: the illusion of precision
  • Patents
  • Litigation
  • FRAND
  • UPC
7 October 2026
Patent assignment not entered in the register: the lesson of the Sony ruling
  • Patents
  • Litigation
  • Case law
  • Saisie-contrefaçon
6 October 2026
Plausibility and the right of priority: the French court faces apixaban
  • Patents
  • Litigation
  • Case law
  • Pharmaceuticals
5 October 2026
Preliminary injunctions and patent applications: the French fault line
  • Application for a preliminary injunction
  • Patents
  • Litigation
  • Case law
  • Pharmaceuticals
4 October 2026
Dosage inventions and inventive step: the strict reading of the French court
  • Patents
  • Litigation
  • Case law
  • Pharmaceuticals
3 October 2026
Pharmaceutical patents and the UPC: is the Court hostile to them?
  • Application for a preliminary injunction
  • Patents
  • UPC
  • Pharmaceuticals
2 October 2026
Brexit and the UPC: where British patent holders now stand
  • Patents
  • Litigation
  • UPC
25 September 2026
Unitary and National Patents: A Quest for Coherence
  • Patents
  • UPC
  • Case law
23 September 2026
The Transitional Period and the UPC: Coordinating Two Judicial Orders
  • Patents
  • Litigation
  • Forum shopping
  • UPC
22 September 2026
Preliminary References and the UPC: the Question of Jurisdiction
  • Patents
  • Litigation
  • UPC
21 September 2026
Appeals before the UPC: what the figures show
  • Patents
  • Litigation
  • Forum shopping
  • UPC
20 September 2026
FRAND devant la JUB : les solutions retenues et les questions ouvertes
  • Patents
  • Litigation
  • FRAND
  • UPC
19 September 2026
SMEs and the UPC: Cost as a Barrier to Access to Justice
  • Patents
  • Litigation
  • UPC
18 September 2026
Procedural Uncertainty and the UPC: Provisional Measures, Evidence and Costs
  • Application for a preliminary injunction
  • Patents
  • Litigation
  • UPC
17 September 2026
The World Without the UPC: How a Successful Court Could Still Disappear
  • Patents
  • Litigation
  • Forum shopping
  • UPC
16 September 2026
G 1/25: the description as a tool for interpreting the claims
  • Patents
  • Litigation
  • UPC
  • Case law
15 September 2026
Pay-for-delay: the CJEU confirms Teva/Cephalon and defines the limits of patent settlement agreements
  • Patents
  • Litigation
  • Contract
  • Case law
  • Pharmaceuticals
14 September 2026
Valeo v. Bosch: the allocation of cases within the UPC, an alternative and not an exception
  • Patents
  • Litigation
  • Forum shopping
  • UPC
  • Case law
11 September 2026
La saisie-contrefaçon, l’arme française que les titulaires étrangers oublient
  • Patents
  • Litigation
  • FRAND
  • UPC
  • Pharmaceuticals
  • Saisie-contrefaçon
10 September 2026
The launch letter before the UPC: preventing urgency for generics and biosimilars
  • Application for a preliminary injunction
  • Patents
  • UPC
  • Case law
  • Pharmaceuticals
5 September 2026
Portfolio strategy and the UPC: where the value of life sciences assets lies
  • Patents
  • UPC
  • Pharmaceuticals
4 September 2026
The UPC's long-arm jurisdiction: how far the arm reaches, where the effect stops
  • Patents
  • Litigation
  • UPC
3 September 2026
The PMAC Rules: patent arbitration through the FRAND lens
  • Patents
  • FRAND
  • UPC
2 September 2026
Acer v Nokia: the contractual turn of FRAND arbitration
  • Patents
  • FRAND
1 September 2026
Tesla v InterDigital: the FRAND undertaking inside the patent pool
  • Patents
  • FRAND
31 August 2026
FRAND licence: the prior question for standard essential patents
  • Patents
  • FRAND
30 August 2026
UPC evidence preservation orders: the UPC saisie in practice
  • Patents
  • UPC
  • Saisie-contrefaçon
28 August 2026
The saisie conservatoire: obtaining evidence in France for foreign proceedings
  • Patents
  • Saisie-contrefaçon
28 August 2026
French saisie-contrefaçon or UPC seizure: the decision matrix
  • Patents
  • Saisie-contrefaçon
29 July 2024
Comparable licenses before the UPC: compelled production and confidentiality clubs
  • Patents
  • FRAND
  • UPC
29 July 2024
UPC’s Order to Produce Evidence: Huawei vs. Netgear
  • Patents
  • FRAND
  • UPC
24 July 2024
Sanofi vs. Amgen: Successful first UPC revocation action and strict assessment of therapeutic antibodies patentability
  • Patents
  • UPC
  • Pharmaceuticals
22 July 2024
The UPC’s first ruling on an infringement action by the Paris local division
  • Patents
  • UPC
6 May 2024
UPC and Proportionality: Will the EU enters through the back door? (From 10xGenomics case to UPC “seizure”)
  • Patents
  • UPC
  • Saisie-contrefaçon
30 April 2024
Release of a treaty on patent law co-authored by Matthieu Dhenne
  • Patents
  • UPC
4 April 2024
UPC “seizure” Part IV: the appeal against the “seizure” order
  • Patents
  • UPC
  • Saisie-contrefaçon
22 March 2024
UPC “seizure” Part III: the “C-Kore” case
  • Patents
  • UPC
  • Saisie-contrefaçon
18 March 2024
UPC seizure Part II: the “OERLIKON” case
  • Patents
  • UPC
  • Saisie-contrefaçon
14 March 2024
The other seizure: the conservatory seizure in France to recover evidence for foreign proceedings
  • Patents
  • Forum shopping
  • Saisie-contrefaçon
14 March 2024
UPC seizure Part I: the texts
  • Patents
  • UPC
  • Saisie-contrefaçon
19 December 2023
FINGOLIMOD or the Blues of Hesitation: can preliminary injunctions be based on a patent application under French law?
  • Patents
  • Litigation
  • Saisie-contrefaçon
25 July 2023
APIXABAN case in France: priority to the patent holder
  • Patentability
  • Patents
  • Pharmaceuticals
5 June 2023
UPC: brief thoughts from a French “UPC Representative”
  • Patents
  • UPC
23 April 2023
Conflicts between UPCA and national laws: a dangerous riddle?
  • Patents
  • UPC
8 March 2023
Saisie-contrefaçon and trade secrets: protecting the seized party
  • Patents
  • Saisie-contrefaçon
  • Trade secrets
1 March 2023
Some light for the sunrise: 5 questions for 5 French UPC judges
  • Patents
  • UPC
26 October 2020
PEMETREXED patent infringement in France: €28 million in damages for Eli Lilly (“France is back”?)
  • Patents
  • Damages and interests
  • Pharmaceuticals
White Dhenne Avocats Logo

Patent litigation counsel.
France, Europe, UPC.

  • +33 (0)1 71 60 61 46
  • contact@dhenne-avocats.fr
  • LinkedIn
  • X ↗
  • 7, rue Commines
    75003 PARIS
© Dhenne Avocats 2026. All rights reserved.
  • Legal notice
  • Cookie policy
  • Privacy policy
  • Join us